Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcinoma

SAN FRANCISCO and SUZHOU, China, June 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-06-28 08:00 6155

Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Association's 81st Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-25 08:00 6863

Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma

SAN FRANCISCO and SUZHOU, China, June 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-23 09:16 20942

Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan Market for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement

SAN FRANCISCO and SUZHOU, China, June 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-06-22 08:00 20255

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-21 08:00 8029

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-18 08:00 3809

Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-15 12:00 4829

Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress

SAN FRANCISCO and SUZHOU, China, June 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-08 08:00 5178

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 8462

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 8299

Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 8301

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 8384

Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-06-03 17:09 5308

Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"

SAN FRANCISCO, U.S. and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno...

2021-06-03 08:00 5688

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

SAN FRANCISCO and SUZHOU, China, June 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-06-01 08:00 4900

Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma

SAN FRANCISCO and SUZHOU, China, May 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-05-25 08:00 11779

U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, May 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX: 01801...

2021-05-18 12:14 13038

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-05-17 09:00 4882

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-04-29 08:00 5486

Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, April 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-04-13 08:00 5111